Ronda N, Haury M, Nobrega A, Coutinho A, Kazatchkine M D
INSERM U28, Hôpital Broussais, Paris, France.
Clin Immunol Immunopathol. 1994 Feb;70(2):124-8. doi: 10.1006/clin.1994.1019.
In the present study, we demonstrate that intravenous immunoglobulin (IVIg) is capable of binding to variable (V) regions of anti-endothelial cell antibodies (AECA) of healthy donors and patients with systemic lupus erythematosus (SLE). Among V regions of AECAs, IVIg selectively recognized certain idiotypes expressed by the autoantibodies of a given individual, in the case of both natural and SLE-associated AECAs. These observations provide new and direct evidence that IVIg interacts idiotypically with V regions of autoantibodies and that the efficacy of such interaction depends on individual autoantibody specificity. Our findings may be relevant for the understanding of the mechanisms that control expression of natural autoantibody activity in serum and for that of the differences in response to IVIg therapy that are seen between patients with autoimmune disease.
在本研究中,我们证明静脉注射免疫球蛋白(IVIg)能够与健康供体及系统性红斑狼疮(SLE)患者的抗内皮细胞抗体(AECA)的可变(V)区结合。在AECA的V区中,IVIg能选择性识别特定个体自身抗体所表达的某些独特型,无论是天然的还是与SLE相关的AECA均如此。这些观察结果提供了新的直接证据,表明IVIg与自身抗体的V区以独特型方式相互作用,且这种相互作用的效果取决于个体自身抗体的特异性。我们的发现可能有助于理解控制血清中天然自身抗体活性表达的机制,以及自身免疫性疾病患者对IVIg治疗反应差异的机制。